AIM ImmunoTech Inc. Common Stock AIM 深 滬
等待開盤 10-28 09:30:00 美东时间
0.1662
+0.002
+1.47%
華盛通- 最 高0.1696
- 今 開0.1674
- 成交量 20.08万股
- 最 低 0.164
- 昨 收 0.1638
- 總市值 663.05万
- 52周最高 1.8799
- 市盈率 靜 --
- 換手率 0.50%
- 52周最低 0.1503
- 委 比 0.00%
- 總股本 3989.48万
- 歷史最高 20.3297
- 量 比 0.39
- 振 幅 3.42%
- 歷史最低 0.1503
- 每 手 1
- 風險率 0.54%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多AIM ImmunoTech Spotlights Growing Attention Around Ampligen® Pancreatic Cancer Strategy as DURIPANC Advances Toward Topline Data
AIM ImmunoTech Inc. highlights recent media coverage on its Ampligen® program targeting immune resistance in metastatic pancreatic cancer. The Phase 2 DURIPANC trial combines Ampligen with AstraZeneca's Imfinzi® and shows promising immune activation and quality of life results. The trial's final Ampligen dosing is complete, with top-line results expected in Q1 2027. Earlier findings from a Netherlands-approved program involving 57 patients also d...
10-01 13:02
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements
AIM ImmunoTech ( ($AIM) ) has issued an announcement. On September 3 and 4, 202...
09-11 05:01
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video
AIM ImmunoTech Inc. announced the release of a new CEO Corner video discussing its scientific strategy for Ampligen®, an investigational TLR3 agonist designed to activate innate immunity and reshape the tumor microenvironment in pancreatic cancer. The company is advancing its Phase 2 DURIPANC study, evaluating Ampligen in combination with durvalumab as maintenance therapy after standard treatment. AIM believes this study could provide insights in...
09-09 13:03
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference
AIM ImmunoTech Inc. (NYSE American: AIM) announced its participation in the Virtual Investor "Why Now" on-demand conference. CEO Thomas Equels presented the Company's investment thesis, emphasizing the pivotal moment for AIM. The presentation highlighted progress in the Phase 2 DURIPANC clinical trial for Ampligen® in metastatic pancreatic cancer, including successful enrollment completion ahead of schedule, dosing of the final patient, and antic...
08-27 13:01
美股大行评级 | 塔吉特获13家大行上调目标价；Moderna携手默沙东齐获大行上调目标价
今日重点评级关注：康托·菲茨杰拉德：维持Ultragenyx Pharmaceutical"超配"评级，目标价从96美元升至103美元；Canaccord Genuity：维持Ultragenyx Pharmaceutical"买入"评级，目标价从81美元升至83美元
08-21 11:40
Ascendiant Capital Maintains Buy on AIM ImmunoTech, Lowers Price Target to $7
Ascendiant Capital analyst Edward Woo maintains AIM ImmunoTech (AMEX:AIM) with a Buy and lowers the price target from $9 to $7.
08-20 18:01
AIM ImmunoTech CEO Urges Biodefense Military Integration
AIM ImmunoTech ( ($AIM) ) has provided an announcement. On August 11, 2026, AIM...
08-11 21:00
AIM ImmunoTech GAAP EPS of -$0.43
AIM ImmunoTech press release (AIM): Q2 GAAP EPS of -$0.43. As of June 30, 2026, AIM reported $9.9 million in cash and cash equivalents, as compared to approximately $3.0 million as of December 31, 202...
08-10 20:40
AIM ImmunoTech Q2 EPS $(0.43) Misses $(0.18) Estimate, Sales $26.000K Up From $25.000K YoY
AIM ImmunoTech (AMEX:AIM) reported quarterly losses of $(0.43) per share which missed the analyst consensus estimate of $(0.18) by 138.89 percent. This is a 88.32 percent increase over losses of $(3.68) per share from the same period last year. The company reported $26.000 thousand in sales this qua...
08-10 20:38
AIM ImmunoTech Announces Final Subjects Receives Last Dose Of Ampligen Under Study Protocol In Phase 2 DURIPANC Clinical Study
AIM ImmunoTech Inc. (NYSE:AIM) ("AIM" or the "Company") today announced that the final subject has received their last dose of Ampligen® (rintatolimod) under the study protocol, reaching this milestone ahead of schedule in the Phase 2 DURIPANC clinical trial evaluating Ampligen in combination with A...
08-03 20:41
